Skip to content

Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis

A Retrospective Study of the Effects of Different Pathologic Phenotypes of Bullous Pemphigoid on Clinical Management and Prognosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06213909
Acronym
BP
Enrollment
318
Registered
2024-01-19
Start date
2024-01-11
Completion date
2024-06-30
Last updated
2024-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bullous Pemphigoid

Brief summary

Bullous pemphigoid (BP) is a chronic autoimmune subepidermal blistering disease primarily affecting the elderly with a significant risk of mortality and morbidity. Various inflammatory cells such as eosinophils, lymphocytes, neutrophils and their granulopoiesis play an important role in the pathogenesis of BP. Infiltration of peripheral blood eosinophils, lymphocytes, and neutrophils into the skin is considered a major feature of BP, making it a heterogeneous disease with different histologic and clinical subtypes. This clinical study was conducted to further investigate the impact of different pathologic phenotypes of BP on the treatment and prognosis of the disease. A retrospective epidemiologic investigative approach was used,and case collection included demographic information, medical history, clinical manifestations, and histopathologic features. Including gender, age, duration of disease, number of days of hospitalization, mucosal involvement, clinical diagnosis before admission, histopathological diagnosis, laboratory tests, concomitant diseases, treatment and its changes in laboratory indexes before and after treatment.

Interventions

OTHERThis is a retrospective analysis of health data from inpatient record, no intervention was designed

This is a retrospective analysis of health data from inpatient record, no intervention was designed

Sponsors

Xijing Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* (1) Patients with Bullous Pemphigoid who were first hospitalized in the Department of Dermatology of Xijing Hospital * (2) Age 0-100 years old, gender is not limited. * (3) Diagnosis is confirmed by clinical, histopathologic, immunopathologic and/or anti-BP180 antibody tests. * (4) Complete skin histopathology information

Exclusion criteria

* (1) Patients with Bullous Pemphigoid who were not first diagnosed in our hospital. * (2) Those who have received systemic glucocorticoid, immunosuppressant, biologic, or other drug therapy within the past month.

Design outcomes

Primary

MeasureTime frameDescription
Bullous Pemphigoid Disease Area Index (BPDAI) severity score10 yearsWe use BPDAI severity score as measure tool

Countries

China

Contacts

Primary ContactShuai Shao, Phd
857746654@qq.com+862984775401
Backup ContactChen Yu, Phd
ycyc_2005@163.com+862984775401

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026